EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine Partners with Repare for Genomic Profiling and Companion Diagnostic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1\/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare's Lunresertib Gets FDA Fast Track for Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Lunresertib

    Menu

    Lunresertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Foundation Medicine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foundation Medicine Partners with Repare for Genomic Profiling and Companion Diagnostic

              Details:

              The collaboration aims to support Repare’s ongoing clinical development of RP-6306 (lunresertib) oral small molecule inhibitor of PKMYT1 alone or with camonsertib for the treatment of neoplasms.

              Lead Product(s): Lunresertib,Camonsertib

              Therapeutic Area: Oncology Product Name: RP-6306

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Repare Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Repare Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Repare's Lunresertib Gets FDA Fast Track for Platinum-Resistant Ovarian Cancer

              Details:

              FDA granted Fast Track designation to RP-6306 (lunresertib) in combination with RP-3500 (camonsertib) for CCNE1 amplified, or FBXW7 or PPP2R1A-mutated platinum-resistant ovarian cancer.

              Lead Product(s): Lunresertib,Camonsertib

              Therapeutic Area: Oncology Product Name: RP-6306

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Repare Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

              Details:

              RP-6306 (lunresertib), a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, is being developed in combination with Debio 0123, an oral, brain-penetrant, highly selective WEE1 kinase inhibitor, for the treatment of advanced solid tumors.

              Lead Product(s): Lunresertib,Debio0123

              Therapeutic Area: Oncology Product Name: RP-6306

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Debiopharm

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Repare Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

              Details:

              The collaboration will explore the synergy between Debio 0123, a potential best-in-class, brain-penetrant, and highly selective WEE1 inhibitor, and RP-6306 (lunresertib), a first-in-class, selective and potent oral, small molecule inhibitor of PKMYT1 with anticancer activity.

              Lead Product(s): Debio 0123,Lunresertib

              Therapeutic Area: Oncology Product Name: Debio 0123

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Debiopharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Repare Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoin...

              Details:

              RP-6306 (lunresertib) is a PKMYT1 inhibitor currently in Phase 1 clinical development a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche.

              Lead Product(s): Lunresertib

              Therapeutic Area: Oncology Product Name: RP-6306

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Canadian Cancer Trials Group

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY